Analyst Daniel Kurnos of Benchmark Co. maintained a Buy rating on Cineverse, retaining the price target of $9.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Daniel Kurnos has given his Buy rating due to a combination of factors that highlight Cineverse’s potential for growth and resilience. Despite recent challenges, such as the underperformance of ‘Toxic Avenger’ at the box office, Cineverse has shown strength in other areas, including strong ancillary market performance with licensing deals from major platforms like Amazon and Hulu. These deals, along with the company’s niche marketing capabilities, suggest a promising future slate of films and projects that could rival past successes.
Additionally, Cineverse’s strategic moves, such as retaining perpetual rights to their content and exploring multiple monetization avenues, demonstrate a low-risk approach that is expected to yield significant returns. The company’s involvement in innovative projects like the Matchpoint pilot further indicates potential for substantial valuation upside. Overall, Kurnos believes that the current market undervalues Cineverse’s prospects, and the stock’s recent performance does not reflect the brighter outlook compared to a year ago.